FundingWatcher
Home / Startups / By venture fund / BioVenture portfolio companies

BioVenture portfolio companies

Updated 16 Nov 2026

http://www.bioventure.com.cn/

BioVenture portfolio companies
One-time CSV
  • 21 funded companies, 18 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-investor-bioventure.csv21 rows × 18 columns
CompanyCityLast roundAmountDate
AusperBioHangzhouSeries C$120.0M2026-08-27
Degron TherapeuticsShanghaiSeries A$40.0M2026-05-14
OrphAI TherapeuticsGuilfordSeries C$58.0M2017-03-30
Allink BiotherapeuticsShanghaiSeries A$47.0M2025-12-16
AccuPulseSuzhouSeries B$14.5M2026-03-13
IMPACT TherapeuticsNanjingSeries D$34.6M2024-11-15
Essentia BiosciencesHaidianSeed$14.3M2026-01-01
Changmugu MedicalBeijingSeries B$84.5M2021-11-10

8 rows of the CSV in 5 of its 18 columns.

21
Startups
$935.4M
Total raised
5
Funded in the last 12 months
$235.8M
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

8 of 21
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
AusperBio AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. Biotech Hangzhou, China Series C $120.0M 2026-08-27 $357.0M Qiming Venture Partners, BioVenture, Hankang Capital +1 51 to 100 2019
Degron Therapeutics Degron Therapeutics discovers molecular glue degraders for cancer treatment. Biotech Shanghai, China Series A $40.0M 2026-05-14 $94.0M Baidu Ventures, BioVenture, New Alliance Capital +2 101 to 250 2021
AccuPulse AccuPulse develops pulsed electric field ablation generators and catheters. Health care Suzhou, China Series B $14.5M 2026-03-13 $72.5M BioVenture, Shanghai Biomedical Industrial Equity Investment Fund, Med-Fine Capital +1 11 to 50 2020
Essentia Biosciences Essentia Biosciences develops cell therapies, gene technology drugs, and medical devices. Biotech Haidian, China Seed $14.3M 2026-01-01 $14.3M BioVenture, Haitang Fund, Beijing Molecular Technology 1 to 10 2021
Allink Biotherapeutics Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. Biotech Shanghai, China Series A $47.0M 2025-12-16 $89.0M Legend Capital, Gaorong Capital, BioVenture +2 11 to 50 2023
IMPACT Therapeutics IMPACT Therapeutics develops similar drugs to treat cancer. Biotech Nanjing, China Series D $34.6M 2024-11-15 BioVenture, Lilly Asia Ventures, Decheng Capital +2 51 to 100 2009
Changsha Morning Shine Changsha Morning Shine is a pharmaceutical company offering CDMO, chemical drug, and biotechnology services. Biotech Changshan, China Series A $14.1M 2023-12-14 $14.1M BioVenture, Jolmo Capital, Sunz Fund 2019
Gachun Biotech Gachun Biotech runs an industrial platform producing active pharmaceutical ingredients and pharmaceutical intermediates. Biotech Chengdu, China Series A $14.1M 2023-11-23 $14.1M BioVenture, Si Chuan Venture Capital 11 to 50 2017

Table 1. BioVenture portfolio companies: the 8 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 21.

Largest rounds

Last 12 months
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 AusperBio AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. Biotech Hangzhou, China Series C $120.0M 2026-08-27 $357.0M Qiming Venture Partners, BioVenture, Hankang Capital +1 51 to 100 2019
2 Allink Biotherapeutics Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. Biotech Shanghai, China Series A $47.0M 2025-12-16 $89.0M Legend Capital, Gaorong Capital, BioVenture +2 11 to 50 2023
3 Degron Therapeutics Degron Therapeutics discovers molecular glue degraders for cancer treatment. Biotech Shanghai, China Series A $40.0M 2026-05-14 $94.0M Baidu Ventures, BioVenture, New Alliance Capital +2 101 to 250 2021
4 AccuPulse AccuPulse develops pulsed electric field ablation generators and catheters. Health care Suzhou, China Series B $14.5M 2026-03-13 $72.5M BioVenture, Shanghai Biomedical Industrial Equity Investment Fund, Med-Fine Capital +1 11 to 50 2020
5 Essentia Biosciences Essentia Biosciences develops cell therapies, gene technology drugs, and medical devices. Biotech Haidian, China Seed $14.3M 2026-01-01 $14.3M BioVenture, Haitang Fund, Beijing Molecular Technology 1 to 10 2021

Table 2. BioVenture portfolio companies: the 5 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 Qiming Venture Partners Venture capital firm Shanghai, China 2 10% 1 AusperBio
2 Med-Fine Capital Venture capital firm Shanghai, China 2 10% 2 Degron Therapeutics, AccuPulse
3 Shanghai Biomedical Industrial Equity Investment Fund Venture capital firm Huangpu, China 2 10% 1 AccuPulse
4 Haitang Fund Venture capital firm Nankai, China 2 10% 1 Essentia Biosciences
5 Hankang Capital Venture capital firm Shanghai, China 1 5% 1 AusperBio
6 Genesis Capital Private equity firm Central, Hong Kong 1 5% 1 AusperBio
7 Cowin Venture Angel group Beijing, China 1 5% 1 Degron Therapeutics
8 Baidu Ventures Venture capital firm Beijing, China 1 5% 1 Degron Therapeutics
9 New Alliance Capital Private equity firm Shanghai, China 1 5% 1 Degron Therapeutics
10 Gaorong Capital Venture capital firm Wangjing, China 1 5% 1 Allink Biotherapeutics
11 Xiamen C&D Emerging Industry Equity Investment Private equity firm Xiamen, China 1 5% 1 Allink Biotherapeutics
12 Lanchi Ventures Venture capital firm Singapore 1 5% 1 Allink Biotherapeutics
13 Legend Capital Venture capital firm Beijing, China 1 5% 1 Allink Biotherapeutics
14 Blue Bay Ventures Venture capital firm California City, United States 1 5% 1 AccuPulse
15 WuXi Healthcare Ventures Venture capital firm Cambridge, United States 1 5%

Table 3. BioVenture portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 20 95% $935.4M
Biotech 10 48% $721.1M
Software 5 24% $219.8M
Artificial intelligence 3 14% $204.0M
Hardware 3 14% $106.0M

Table 4. BioVenture portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Seed 4 19% $15.7M
Series A 9 43% $14.1M
Series B 3 14% $84.5M
Series C 2 10% $120.0M
Series D+ 3 14% $34.6M

Table 5. BioVenture portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
China 20 95%
United States 1 5%

Table 6. BioVenture portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Shanghai 4 19%
Beijing 3 14%
Hangzhou 2 10%
Suzhou 2 10%
Shenzhen 2 10%
Guilford 1 5%
Nanjing 1 5%
Haidian 1 5%
Changshan 1 5%
Zhoushan 1 5%
Chengdu 1 5%
Changsha 1 5%

Table 7. BioVenture portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
August 2026 1 20% $120.0M
May 2026 1 20% $40.0M
March 2026 1 20% $14.5M
January 2026 1 20% $14.3M
December 2025 1 20% $47.0M

Table 8. BioVenture portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 4 19% $188.8M
2025 1 5% $47.0M
2024 7 33% $49.8M
2023 4 19% $42.0M
2022 2 10% $20.1M
2021 1 5% $84.5M

Table 9. BioVenture portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 1 5%
2020 to 2022 5 24%
2015 to 2019 9 43%
2010 to 2014 4 19%
Before 2010 2 10%

Table 10. BioVenture portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 2 11%
11 to 50 7 39%
51 to 100 4 22%
101 to 250 2 11%
251 to 500 1 6%
501 to 1,000 1 6%
1,001 to 5,000 1 6%

Table 11. BioVenture portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many BioVenture portfolio companies are on the list?
21, in the file dated 16 November 2026. 5 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 21 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

BioVenture portfolio companies: 21 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Portfolio companies by country

Portfolio companies by city

Other venture fund portfolios

Cite: FundingWatcher, 21 startups, 16 November 2026. https://fundingwatcher.com/startups/investor/bioventure/